The prospective research of the effect of topical ripasudil for pterigyum

The prospective research of the effect of topical ripasudil for pterigyum - The effect of topical ripasudil for pterygium

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027512

Enrollment

Registered

2017-05-29

Start date

2017-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium

Interventions

0.4% ripasudil is instilled for treatment group twice a day (morning and evening). Instillation is continued for six months. No treatment.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pterygium does not regress spontaneously during observation period for two months. 2) The edge of pterygium is smaller than two thirds of corneal radius. 3) A person is more than 20 years old. 4) The consent of the document is obtained.

Exclusion criteria

Exclusion criteria: 1) Persons who are contraindicated for the test drugs. 2) Persons who are allergic to ripasudil. 3) Persons who had severe corneal, conjunctival and intraocular disease. 4) Persons who are thought as inappropriate by principal or subprincipal doctors.

Design outcomes

Primary

Measure	Time frame
We capture the image of anterior segment of eyes and evaluate the time-dependent change of the area of pterygium.	—

Countries

Japan

Contacts

Public ContactOno Takashi

Miyata Eye Hospital Ophthalmology

ono@miyata-med.ne.jp0986-22-1441

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026